Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism

Pulmonary Embolism Clinical Trial

— EOLE  

Official title:

Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05103670
• Other study ID #: 29BRC21.0139 (EOLE)
• Status: Recruiting
• Phase: N/A
• Start date: June 22, 2023
• Est. completion date: December 22, 2025

Study information

• Verified date: July 2023
• Source: University Hospital, Brest
• Contact: Pierre-Yves LE ROUX
• Phone: +332 98 22 31 17
• Email: pierre-yves.leroux[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.

The "RAMBO" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and/or persistent dyspnea despite anticoagulant therapy.

Ventilation/Perfusion (V/Q) PET/CT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V/Q imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.

The EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V/Q PET/CT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V/Q PET/CT imaging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: December 22, 2025
• Est. primary completion date: December 22, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Patient included in the RAMBO study, whose inclusion criteria are: Age = 18 years; Patient treated with at least 3 months and up to 8 months of anticoagulation for an acute symptomatic PE diagnosed according the ESC and ACCP guidelines; Patients who have a PembQol score = 10% and whose total scores for the subgroups Q1 (dyspnea) and Q4 (impact of daily life) are = 10%.

• Patients planned to be randomized

• Abnormal conventional V/Q scan at V1

• Give consent to participate to the EOLE study

Exclusion Criteria:

• Non inclusion criteria of the RAMBO trial:

• Previsible inability to perform the effort test and/or PR

• Presence of CTEPH according to international guidelines

• Patients treated for acute PE with anticoagulants for more than 8 months

• Active cancer or in remission for less than two years

• Dyspnea post - COVID due to parenchymal injuries

• Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae

• Physical or psychological inability to undertake PR

• Isolated or more distal segmental PE

• Neuro-muscular disease with PR contraindication.

• Cardiac insufficiency (unstable coronary artery disease)

• Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)

• Chronic dyspnea MMRC = 2 before PE

• Cardiac or respiratory rehabilitation in the previous year

• Indication to urgent PR within 6 months at the time of inclusion

• Life expectancy of less than 12 months

• Inability to give consent

• Patient under guardianship or curatorship

• Patient deprived of liberty by an administrative or judicial decision

• Patient has not social security affiliation or who don't beneficiary of such social security

After initial PR work up, patients with following criteria cannot be included:

• Incapacity to perform the effort test

• Effort test stopped because of hemodynamic intolerance

• Cardiac failure discovered after PR work up

Related Conditions & MeSH terms

• Dyspnea
• Embolism
• Pulmonary Embolism

Intervention

Procedure:
• Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.

Locations

Country	Name	City	State
France	LEROUX Pierre-Yves	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary vascular obstruction index (PVOI) on V/Q PET/CT imaging.	Expressed as a percentage of whole lung	3 months
Secondary	Pulmonary ventilation impairment index on V/Q PET/CT imaging.	Expressed as a percentage of whole lung	3 months